Ingenuity Health to Present New Clinical Research at U.S. Psychiatric and Mental Health Congress

BALTIMORE, Sept. 10, 2015 /PRNewswire/ -- Ingenuity Health, a service of Ameritox, Ltd., and a leading provider of monitoring solutions to behavioral health clinicians, today announced new clinical research studies that examine the rate of medication non-adherence and the use of illicit substances and non-prescribed drugs in patients prescribed antipsychotic drugs. The research explores the resulting treatment outcomes and highlights the utility and value of urine drug monitoring in patients diagnosed with serious mental illness.

Photo - http://photos.prnewswire.com/prnh/20150910/265513LOGO

"The treatment of those suffering from major depressive disorder, bipolar disorder or schizophrenia is complicated enough as it is – but throw potential medication non-adherence and abuse of illicit drugs into the mix and the risks for patients and those around them skyrocket," said Tom Smith, MD, Chief Medical Officer of Ameritox. "Urine drug monitoring can help remove some of the guesswork clinicians have to make in treating patients, which can lead to better clinical outcomes."

The research will be presented in poster form on Friday, Sept. 11 from 1:30-2:30 pm at the U.S. Psychiatric and Mental Health Congress held in San Diego. The posters are titled: "Adherence to Treatment With Antipsychotic Medications Among Patients With Schizophrenia, Major Depressive Disorder, or Bipolar Disorder;" "An Evaluation of Urine Drug Monitoring in the Treatment of Patients With Serious Mental Illness;" "Predictors of Medication Adherence Evaluated by Urine Drug Monitoring in Patients Prescribed Antipsychotic Agents;" and "Value of Comprehensive Urine Drug Monitoring in Patients Prescribed Antipsychotic Medications."

In addition to talking with members of the Ingenuity Health clinical research team during the poster session, Congress attendees are welcome to meet with staff by visiting the Ingenuity Health hospitality room, located in Room 23A at booth #530.

About Ingenuity Health

As a service of Ameritox^SM, a national leader in medication monitoring solutions, Ingenuity Health utilizes urine drug monitoring to provide highly reliable data and analysis that helps doctors and behavioral health specialists better treat patients diagnosed with SMI.

Visit the Ingenuity Health website at: www.ingenuityhealth.com
Follow Ingenuity Health on Twitter: www.twitter.com/ingenuityhealth

About Ameritox

Ameritox helped pioneer the prescription drug monitoring necessary to address the national epidemic of prescription drug misuse, abuse, and diversion. As a trusted leader in Pain Medication Monitoring Solutions^SM, Ameritox provides medical and business professionals with health care solutions that can help improve patient care and prevent tragedy. Ameritox, headquartered in Baltimore, Md., has laboratory facilities in Greensboro, N.C.

Visit the Ameritox website at: www.ameritox.com
Follow Ameritox on Twitter: www.twitter.com/ameritox

Lon Wagner, Ameritox
Office: 336-387-7742
Email

Genevieve Rozansky, 30 Point Strategies
Office: 202-509-0794
Email

SOURCE Ingenuity Health

Related Links

http://www.ingenuityhealth.com